

Assoc. Prof. METİN DEMİR

Personal Information

Email: metin.demir@ogu.edu.tr

Web: <https://avesis.ogu.edu.tr/metin.demir>

International Researcher IDs

ORCID: 0000-0003-1394-1101

Yoksis Researcher ID: 384037

Education Information

Post Doctorate of Medicine, Hacettepe University, Turkey 2015 - 2018

Expertise In Medicine, Diğer (Kurumlar,hastaneler Vb.), Turkey 2009 - 2014

Undergraduate, Istanbul University, Turkey 2003 - 2009

Dissertations

Expertise In Medicine, Proteinürisi olan kronik renal yetersizlikli diabetik hastalarda kardiyovasküler risk faktörlerinin ve kan ürik asit düzeylerinin değerlendirilmesi, Diğer (Kurumlar,hastaneler Vb.), 2014

Research Areas

Medicine, Internal Medicine Sciences, Internal Diseases, Oncology, Health Sciences

Academic Titles / Tasks

Assistant Professor, Eskisehir Osmangazi University, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, 2022 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **The Naples prognostic score in esophagus cancer: Prognostic and beyond**
Demir M., Demircan N. İ. C.
BULLETIN DU CANCER, vol.110, no.10, pp.1027-1040, 2023 (SCI-Expanded)
- II. **Dynamic changes in systemic immune-inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy**
Demircan N. C., Atci M. M., Demir M., Isik S., Akagunduz B.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol.19, no.1, pp.104-112, 2023 (SCI-Expanded)
- III. **The CONUT score is prognostic in esophageal cancer treated with chemoradiotherapy**
Demir M., Demircan N. C.
SAUDI JOURNAL OF GASTROENTEROLOGY, vol.29, no.2, pp.119-126, 2023 (SCI-Expanded)
- IV. **The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study**

Atci M. M., Akagunduz B., Demir M., Arikan R., Ay S., Ozer M., Ayhan M., Cil I., Demir N., Ozyurt N., et al.

JOURNAL OF CHEMOTHERAPY, vol.35, no.1, pp.19-28, 2023 (SCI-Expanded)

V. **Effect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated with Concurrent Chemoradiation: A Multicenter Study**

Atci M. M., Akagunduz B., Demir M., Yilmaz B. D., Telli T. A., Can O., Cil I., Aydin S. G., Ozyurt N., Onder A. H., et al.

ONCOLOGY RESEARCH AND TREATMENT, vol.45, no.5, pp.254-260, 2022 (SCI-Expanded)

VI. **The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy**

Sahin T., Dizdar Ö., Ozdemir N., Zengin N., Ates O., Oksuzoglu B., Şendur M. A. N., Bilgin B., Demir M., Bozbulut U. B., et al.

ANTI-CANCER DRUGS, no.3, pp.289-294, 2019 (SCI-Expanded)

VII. **Comparison of prognosis and clinical features between synchronous bilateral and unilateral breast cancers**

Karakas Y., Kertmen N., Lacin S., Aslan A., Demir M., Ates O., Aksoy S., Altundag K.

JOURNAL OF BUON, no.3, pp.623-627, 2017 (SCI-Expanded)

Articles Published in Other Journals

I. **Surgery: The Fundamental Part of Treatment in Elderly Esophageal Squamous Cell Carcinoma Patients**

Demir M.

Eurasian Journal of Medical Investigation, vol.7, no.2, pp.162-169, 2023 (Peer-Reviewed Journal)

II. **Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience**

Demir M., Güven D. C., Aktaş B. Y., Güner G., Aktepe O. H., Taban H., Karakaş Y., Kılıçkap S., Kars S. A., Türker F. A., et al.

SOUTH ASIAN JOURNAL OF CANCER, vol.11, no.4, pp.287-292, 2022 (ESCI)

III. **Evidence for diverse prognosis in high-grade serous ovarian carcinoma: solid, pseudoendometrioid, and transitional-like; so-called “set morphology” and progesterone receptor status**

Üner H., Demir M., Göksülük D., Kars S. A., Üner M., Usubütün A.

TURK PATOLOJİ DERGİSİ, vol.38, no.3, pp.240-250, 2022 (ESCI)

IV. **Controlling Nutritional Status (CONUT) Score Is a Prognostic Factor for Patients with Gastric Cancer Treated by Perioperative FLOT**

Akagündüz B., Demir M., Atci M. M.

JOURNAL OF GASTROINTESTINAL CANCER, vol.53, no.3, pp.571-580, 2021 (ESCI)

V. **Multimodality Treatment in Malignant Peripheral Nerve Sheath Tumors**

Karakaş Y., Dizdar Ö., Kösemehmetoğlu K., Bozbulut U. B., Demir M., Gedikoğlu M. G., Söylemezoğlu A. F., Türker F. A., Kars S. A.

Journal of oncological sciences, vol.6, no.1, pp.23-28, 2020 (Peer-Reviewed Journal)

VI. **Comparison of Coronary Artery Calcium Scores with Platelet Volume and Uric Acid Levels in Patients Who Underwent Coronary Artery Imaging with Computed Tomography**

Bulunmaz M., Demir M., Börkür Uysal B., Erdem S., Polat H., Ergüney M. H.

Galenos Yayınevi, vol.16, no.1, pp.5-9, 2015 (ESCI)

VII. **Role of Uric Acid in Determining Cardiovascular Risk**

Demir M., Bulunmaz M., Müderrisoğlu C., Köse Ş., Erdem S., Polat H.

Galenos Yayınevi, vol.15, pp.203-208, 2015 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

I. **The Effect of Adjuvant Chemotherapy Initiation Time on Survival in High Risk Stage II and Stage III**

Colon Cancer

Yalınkılıç M., Yıldız B., Karateke Y. S., Demir M.

13th International Gastrointestinal Cancer Conference, Antalya, Turkey, 30 November 2023, pp.8-9

- II. **THE EFFECT OF ADJUVANT CHEMOTHERAPY INITIATION TIME ON SURVIVAL IN HIGH-RISK STAGE II AND STAGE III COLON CANCER**
Yalınkılıç M., Yıldız B., Sağdıç Karateke Y., Demir M.
13TH INTERNATIONAL GASTROINTESTINAL CANCERS CONFERENCE, Antalya, Turkey, 30 November 2023
- III. **Kolon Metastazlı Nüks Adrenokortikal Karsinom Olgusu**
KARATEKE Y. S., YILDIZ B., AĞDAŞ G., CANAZ F., GÜNDOĞDU E., DEMİR M.
6. GENÇLERLE ONKOLOJİYE BAKIŞ KONGRESİ, Antalya, Turkey, 23 - 26 November 2023, pp.27-28
- IV. **NEOADJUVAN TEDAVİ ALMADAN OPERE EDİLEN MİDE ADENOKANSERİ HASTALARINDA ADJUVAN FLOT KEMOTERAPİSİNİN ETKİNLİK ve GÜVENLİĞİ**
DEMİR M.
24. ULUSAL KANSER KONGRESİ, Turkey, 9 - 13 November 2022
- V. **TIBBİ ONKOLOGLARIN COVID-19 PANDEMİSİNDE G-CSF KULLANIMIYLA İLGİLİ KLİNİK PRATİKTEKİ DEĞİŞİKLİKLERİNİN DEĞERLENDİRİLMESİ**
TABAN H., AKTAŞ B. Y., GÜVEN D. C., YILDIRIM H. Ç., YILMAZ F., Yaşar S., DEMİR M., AKIN S., KILIÇKAP S.
8. Türk Tıbbi Onkoloji Kongresi, Turkey, 03 November 2021
- VI. **MEME KANSERİ HASTALARINDA BRCA TESTİ İÇİN NCCN KRİTERLERİNİN İNCELENMESİ**
DEĞİRMENCİLER R. F., AKTAŞ B. Y., TABAN H., GÜVEN D. C., GÜNER G., YILDIRIM H. Ç., DEMİR M., KERTMEN N., ARIK Z., DİZDAR Ö., et al.
8. Türk Tıbbi Onkoloji Kongresi, Turkey, 03 November 2021
- VII. **GASTRIC CANCER MANAGEMENT IN OLDER THAN 70-YEAR-OLD PATIENTS**
DEMİR M.
ONKAD-"IX. ONCOSURGERY DAYS" Advances in HPB and GI Cancer Surgery and Systemic Treatments, Turkey, 26 - 27 June 2021
- VIII. **METASTATİK KOROİDAL MELANOM: TEK MERKEZ DENEYİMİ**
AKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., KILIÇKAP S., ÇELİK İ.
2. ULUSAL İMMÜNÖTERAPİ VE ONKOLOJİ KONGRESİ, Turkey, 31 October - 04 November 2018
- IX. **ANTI-EGFR MONOKLONAL ANTİKORU NİMOTUZUMAB İLE TAM YANITLI OLARAK İZLENEN BİR ANAPLASTİK ASTROSİTOM VAKASI**
DEMİR M., BOZBULUT U. B., LAÇİN Ş., KILIÇKAP S.
7. Türk Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2018
- X. **SORAFENİB TEDAVİSİ İLE İZLENMEKTE OLAN BİR METASTATİK TIROID PAPİLLER KANSERİ OLGUSU**
DEMİR M., BOZBULUT U. B., LAÇİN Ş., KILIÇKAP S.
7. Türk Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2018

Scientific Refreeing

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, National Scientific Refreed Journal, October 2023

Osmangazi Tıp Dergisi, National Scientific Refreed Journal, March 2023